Miragen Therapeutics (MGEN) Sees Coverage Initiated By Oppenheimer with a $13 Price

January 13, 2018 - By Adrian Mccoy

 Miragen Therapeutics (MGEN) Sees Coverage Initiated By Oppenheimer with a $13 Price

Why Has Oppenheimer Given Miragen Therapeutics (MGEN) a $13 Price Target

In analysts report issued today, Oppenheimer analysts has begun Miragen Therapeutics (MGEN) coverage with “Outperform” rating, and a $13 target.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 6 analysts covering Miragen Therapeutics (MGEN), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $15.75’s average target is 76.77% above currents $8.91 stock price. Miragen Therapeutics had 9 analyst reports since February 21, 2017 according to SRatingsIntel. Wedbush initiated it with “Outperform” rating and $19.0 target in Tuesday, February 21 report. Chardan Capital Markets maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Monday, August 14 with “Buy” rating. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Monday, October 16 by Wedbush. Oppenheimer initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) rating on Thursday, January 11. Oppenheimer has “Buy” rating and $13.0 target. On Friday, August 18 the stock rating was maintained by Wedbush with “Buy”. The firm earned “Buy” rating on Friday, December 1 by Wedbush.

The stock increased 4.09% or $0.35 during the last trading session, reaching $8.91. About 140,851 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on March, 23. After $-0.27 actual earnings per share reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 7.41 % negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $198.78 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Streetinsider.com which released: “Oppenheimer Starts miRagen Therapeutics (MGEN) at Outperform” on January 11, 2018, also Globenewswire.com with their article: “miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris” published on January 05, 2018, Seekingalpha.com published: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q3 2017 Results …” on November 10, 2017. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Globenewswire.com and their article: “miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare …” published on September 01, 2017 as well as Globenewswire.com‘s news article titled: “miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide …” with publication date: October 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: